Medtronic: Margin Inflection With Diabetes Spin

Medtronic (MDT) is initiated with a Strong Buy and a $161 price target, driven by an anticipated structural margin inflection largely underestimated by the Street. The pending Diabetes spin-off is expected to immediately uplift operating margins by 100 basis points, while a robust innovation pipeline, particularly in Cardiac Ablation Solutions and Structural Heart, is poised to accelerate core franchise growth. Analysts believe the market is overly focused on temporary FY26 tariff headwinds and understates the significant profitability step-change expected in FY27, projecting an FY27E EPS of $6.20 and an 87% upside to the price target as MDT re-rates towards higher-multiple medtech peers.

Analysis

Medtronic (MDT) is positioned at a structural inflection point for margin expansion, a development the market appears to be underestimating. The primary catalyst is the pending spin-off of its lower-margin Diabetes business, which is projected to immediately lift consolidated operating profit margins by approximately 100 basis points. This move is complemented by a robust innovation pipeline of over 120 assets, with the Cardiac Ablation Solutions (CAS) and Structural Heart divisions driving double-digit growth, supported by the market-share-capturing Evolut platform and the procedurally efficient PulseSelect system. While our financial model is conservative for FY26, projecting an EPS of $5.45 (1.8% below consensus) due to a more cautious view on tariff impacts, it is significantly more bullish for FY27. We forecast an FY27 EPS of $6.20, 3.7% above the Street, driven by post-spin accretion and pronounced operating leverage. The current valuation, based on a 26.0x P/E on our FY27 estimate, implies an 87% upside to our $161 price target and represents a steep discount to the peer median of 42.9x, suggesting a significant re-rating potential as these catalysts unfold. Key risks to this thesis are concentrated in potential tariff extensions beyond FY26 and regulatory or product integrity setbacks, though the analysis suggests an asymmetric risk profile skewed heavily to the upside for long-term investors.

Key Decisions for Investors

• Investors should consider looking past the anticipated FY26 earnings weakness, driven by temporary tariff headwinds, and focus on the significant margin inflection and EPS acceleration projected for FY27.
• The successful execution and timing of the Diabetes business spin-off is a critical catalyst to monitor, as it is expected to unlock an immediate 100 basis point margin improvement and trigger a re-rating of the core business.
• Closely track the commercial performance and market adoption within the Cardiac and Structural Heart franchises, as their sustained double-digit growth is fundamental to achieving the out-year revenue and earnings targets.
• Given the valuation discount relative to peers and the identified catalysts, the current entry point may offer an asymmetric risk/reward profile, but positions should be managed with an awareness of specific downside risks from prolonged trade disputes or unforeseen regulatory hurdles.